Rheumatoid Arthritis

Xeljanz treat adults with moderate to severe active RA who have had an inadequate response or intolerance to methotrexate.

The FDA is reviewing a once-daily formulation of Pfizer's tofacitinib citrate (Xeljanz) for rheumatoid arthritis (RA).

Productivity and absenteeism improved in patients with chronic inflammatory arthritides.

Treating patients within 3 months of the onset of symptoms may prove to be beneficial.

Patients achieve drug-free remission with less expensive biologic drugs during first 2 years of treatment.

Drug shows improvement in skin thickening with active treatment.

Either patient group in need of more intensive treatment to reduce surgery risk.

Drug found to improve physical function.

Therapy disrupts signals that fuel inflammation.

Novel drug target found in cells directly responsible for cartilage damage in affected joints.

Unbalanced gut bacteria can lead to autoimmune disorders such as type 1 diabetes, rheumatoid arthritis, and multiple sclerosis.

Study may add to the ability to predict RA outcomes.

Gene may help identify clue to separation of overactive and underactive immune activity.

Nearly 30% of total biologic drug costs paid out-of-pocket.

Novel pathway regulating immune cell movement may help eliminate debilitating effects of several serious diseases.

Condition shares pathogenic mechanisms with rheumatoid arthritis.

Genetic variants found that are associated with psoriatic arthritis, but not psoriasis.

Mosquito-borne virus causes joint pain and swelling similar to rheumatoid arthritis.

In 2014, the FDA approved notable new therapies for the treatment of cancer, bleeding disorders, inflammatory conditions, cystic fibrosis, pulmonary fibrosis, HIV, hepatitis C, multiple sclerosis, angioedema, and other conditions.

Patients with celiac disease are known to be deficient in the amino acid L-carnitine, a nutrient essential for muscle energy production.

Disease scores with biosimilar equivalent to those who received reference product.

Amgen has announced positive results of a phase 3 study evaluating its investigational drug, ABP 501, a biosimilar candidate to AbbVie's fully human anti-tumor necrosis factor alpha monoclonal antibody, adalimumab, in patients with moderate-to-severe rheumatoid arthritis.

Specific type of non-steroidal anti-inflammatory drugs can increase heart attack risk for some people.

Medication shows promising results in phase 3 study.

Patients with autoimmune conditions have an increased risk of developing shingles due to immune-suppressing treatment regimens.

More severe psoriasis associated with clinically significant cardiovascular risk.

Patients significantly overweight or underweight less likely to remain in remission.

First-line therapy with abatacept in combination with methotrexate achieved significantly higher rates of stringent measures of remission in patients with early rheumatoid arthritis.

Researchers find optimal combination and dosage for three common antirheumatic drugs.

Methotrexate injection treats patients with rheumatoid arthritis, polyarticular-course juvenile idiopathic arthritis, and psoriasis.